1	Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A			
2		Mendelian Randomization Study		
3				
4	Ste	ephen Brennan, MB ^{1,2} , Peter J. Kelly MD ^{1,3,4} , Sarah Gorey, MB ³ , Pádraig Synnott, MB ³ ,		
5	Di	pender Gill, MB, ⁵ Martin Dichgans, MD ^{6,7,8} , Marios Georgakis, PhD ^{6,9,10} , Marie-Joe Dib,		
6	Ph	D ¹¹ , Eloi Gagnon, MA ¹² , Niall Mahon, MB ¹³ , Gavin Blake, MB ¹³ , Christina Jern, PhD ^{14,15} ,		
7	Ηu	igh S. Markus, PhD ¹⁶ , William Whiteley PhD ^{17,18} , John J. McCabe, PhD ^{3,4,19} .		
8				
9	1.	Stroke Service, Department of Neurology, Mater Misericordiae University Hospital, Dublin,		
10		Ireland		
11	2.	School of Medicine, University of Galway, Galway, Ireland		
12	3.	Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland,		
13	4.	School of Medicine, University College Dublin, Dublin, Ireland		
14	5.	Department of Epidemiology and Biostatistics, School of Public Health, Imperial College		
15		London, London, UK.		
16	6.	Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany		
17	7.	German Center for Neurodegenerative Disease, Munich, Germany		
18	8.	Munich Cluster for Systems Neurology (SyNergy), Munich, Germany		
19	9.	Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States		
20	10.	Program in Medical and Population Genetics, Broad Institute of Harvard and the Massachusetts		
21		Institute of Technology, Boston, United States		
22	11.	Cardiovascular Division, Perelman School for Advanced Medicine, University of Pennsylvania,		
23		Philadelphia, USA.		
24	12.	Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Laval		
25		University, Québec (QC), Canada		
26	13.	Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland		

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 27 14. Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg,
- 28 Sweden
- 29 15. Department of Laboratory Medicine, Institute of Biomedicine, the Sahlgrenska Academy,
- 30 University of Gothenburg, Gothenburg, Sweden
- 31 16. Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge,
- 32 Cambridge, United Kingdom
- 33 17. Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
- 34 18. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- 35 19. Stroke Service, Department of Geriatric Medicine, Mater Misericordiae University Hospital,
- 36 Dublin, Ireland
- 37
- 38 Corresponding author: Stephen Brennan, MB,
- 39 Stroke Service, Department of Neurology,
- 40 Mater Misericordiae University Hospital, Dublin, Ireland
- 41 T: +353-1-803-2000, E: stephenbrennan@mater.ie
- 42
- 43 Total manuscript word count (including Title Page, Abstract, Text, References, and Figures
- 44 Legends): 7033
- 45
- 46
- 47
- 48
- 49
- 50
- -
- 51
- 52

53 Abstract

54 **Background:** Inflammation is an emerging target for the prevention and treatment of cardiovascular disease (CVD). This drug-target Mendelian randomization (MR) study aimed 55 56 to predict the on-target effects of IL-18 inhibition on CVD risk. Furthermore, we aimed to 57 explore the effects of IL-18 inhibition on cardio-metabolic traits, cardiac structure, and 58 function, and identify potential adverse outcomes. 59 60 Methods: We selected five independent circulating IL-18-lowering variants around the IL-18 61 gene locus from the Systematic and Combined AnaLysis of Olink Proteins (SCALLOP) 62 consortium. We then performed two-sample MR analyses to investigate the association of 63 genetically proxied IL-18-inhibition on downstream inflammatory markers, risk of CVD, 64 cardiac magnetic resonance (CMR) imaging measurements of cardiac structure and function,

65 cardiometabolic traits, and a selection of potential adverse effects. We utilized data from the

66 UK Biobank, Cardiogram, GIGASTROKE, and other large genomic consortia (sample range:

- 67 3,301-1,320,016).
- 68

69 **Results:** Following correction for multiple comparisons, one standard deviation (SD) lower 70 in genetically-predicted circulating IL-18 was associated with reductions in downstream 71 biomarkers of IL-18 signaling, including C-reactive protein (SD change -0.02, 95% CI -0.03, 72 -0.02), tumor necrosis factor (SD change -0.19, CI -0.25, -0.14), interferon-gamma (SD 73 change -0.15, CI -0.22, -0.08), and CXCL10 (SD change -0.13, CI -0.16, -0.09). Lower 74 genetically-predicted IL-18 levels were associated with reduced risk of cardio-embolic stroke 75 (Odds Ratio [OR] 0.85, CI 0.79-0.92), but not other stroke subtypes. Furthermore, lower genetically predicted IL-18 levels were associated with reduced risk of peripheral arterial 76 77 disease (OR 0.91, CI 0.84-0.97), atrial fibrillation (OR 0.94, CI 0.89-0.99), and heart failure

78	(OR 0.84, CI 0.77-0.92), as well as improvements in CMR traits, including a reduction in left
79	atrial volume (β -0.02, CI -0.03, -0.00). Lower genetically-predicted IL-18 levels were
80	associated with lower risk of chronic kidney disease, autoimmune diseases, a favorable
81	cardio-metabolic profile, and higher odds of lung cancer, but not infections.
82	
83	Conclusions:
84	Our study provides genetic support that impaired IL-18 signaling may be causally associated
85	with a lower risk of cardio-embolic stroke, possibly mediated through prevention of cardiac
86	re-modelling, heart failure and atrial fibrillation. IL-18 represents a potential target for anti-
87	inflammatory therapy in stroke and CVD that warrants further investigation in clinical trials.
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	
101	
102	

103 Clinical Perspective

104 What is new?

105	•	Using multi-omic data, this Mendelian Randomization study provides evidence that
106		IL-18 lowering is associated with a lower lifetime risk of cardiac remodeling, heart
107		failure, and cardio-embolic stroke.
108	•	A significant proportion of the protective effect of impaired IL-18 signaling on cardio-
109		embolic stroke was mediated through a reduced risk of AF.
110	What a	are the clinical implications?
111	•	These data provide compelling evidence that the IL-18 signaling pathway is a
112		promising druggable target for the treatment of heart failure and the prevention of
113		cardio-embolic stroke.
114	•	Several monoclonal antibodies targeting IL-18 are in development for the treatment of
115		atopic dermatitis and could be considered for re-purposing for cardiovascular disease.
116		
117		
118		
119		
120		
121		
122		
123		
124		
125		
126		
127		

128 Abbreviations

- 129 HF: Heart failure
- 130 NLRP: NOD-like receptor family pyrin domain-containing
- 131 AF: Atrial fibrillation
- 132 IL-18: Interleukin-18
- 133 CMR: Cardiac magnetic resonance
- 134 CRP: C-reactive protein
- 135 IFN-γ: Interferon-gamma
- 136 CVD: cardiovascular disease
- 137 MR: Mendelian randomization
- 138 GWAS: Genome-wide association study
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152

153 Introduction

154 Inflammation has emerged as a promising target for the treatment of atherosclerosis and the secondary prevention of coronary events.^{1, 2} The first anti-inflammatory trials for secondary 155 prevention after stroke have primarily focused on the therapeutic potential of these agents in 156 patients with atherosclerotic mechanisms and excluded patients with cardio-embolic stroke.³ 157 158 However, several complementary lines of evidence also support the importance of inflammatory mechanisms in the pathophysiology and progression of heart failure (HF), atrial 159 160 fibrillation (AF), and cardio-embolic stroke. Animal models provide compelling data that the 161 NOD-like receptor family pyrin domain-containing 3 (NLRP) inflammasome is upregulated 162 in cardiomyocytes in the pathogenesis of AF and promotes structural and electrical atrial remodeling.⁴ Inflammatory signaling is implicated in several pathways central to the 163 164 pathophysiology of HF, including mitochondrial dysfunction, calcium homeostasis, cardiac fibrosis, and impaired cardiomyocyte contractility.^{5, 6} Inflammatory markers are associated 165 with incident AF in population-based studies^{7,8} and AF-related stroke.⁹ Despite these 166 promising data, the results of the first RCTs of anti-inflammatory therapies in HF,^{10, 11} and 167 AF¹² have been neutral. 168

169

170 The NLRP3 inflammasome mediates some of its effects through activation of interleukin- 1β

171 (IL-1 β) via caspase-1 and leads to downstream IL-6 expression. Pre-clinical,¹³

172 observational,^{14, 15} and genetic studies¹⁶ have coalesced to identify the IL-1β-interleukin-6

173 (IL-6) signaling pathway as a promising target for risk reduction in cardiovascular disease¹⁷

and stroke.¹⁸ Significantly less attention has been given to the role of interleukin-18 (IL-18),

175 which is also cleaved to its active form by caspase-1 following activation by the NLRP3

176 inflammasome.¹³ IL-18 is a potent pro-inflammatory cytokine that promotes atherosclerotic

177 plaque progression in pre-clinical work.¹³ However, experimental data have also

178	demonstrated that IL-18 signaling plays a key role in cardiomyocyte hypertrophy, ventricular
179	dysfunction, and cardiac fibrosis. ¹⁹⁻²² Elevated IL-18 levels are observed in patients with HF
180	and correlate with disease severity, but whether this inflammatory response is a cause or a
181	consequence of the pathogenesis of HF is unknown. ²³ Some, but not all, prospective cohort
182	studies have reported that IL-18 is associated with incident coronary events ²⁴⁻²⁶ and HF, ^{24, 27}
183	but not incident stroke. ²⁴ It remains uncertain whether pharmacological inhibition of the IL-
184	18 signaling pathway is a viable treatment option for a variety of cardiovascular diseases,
185	including coronary disease, stroke, AF, and HF.
186	
187	In the absence of RCTs of therapeutics targeting the IL-18 signaling pathway for the
188	treatment of cardiovascular disease, genetic studies can offer valuable insights into the on-
189	target effect of these pharmacological agents. ^{28, 29} Drug-target Mendelian Randomization
190	(MR) employs genetic variants associated with the levels or activity of drug-target proteins,
191	thus serving as proxies for pharmacological agents. ²⁸ The primary aim of this study is to
192	explore the potential benefit of IL-18 inhibition on cardiovascular outcomes using a drug-
193	target MR approach.
194	
195	Methods
196	Study design

We used MR to assess the causal association between genetically proxied downregulation of IL-18 signaling and: 1) cardiovascular disease outcomes, with replication in non-overlapping samples where possible; 2) cardiometabolic and inflammatory traits, including cardiac magnetic resonance (CMR) measures of cardiac structure and function; and 3) potential adverse and beneficial effects associated with reduced IL-18 signaling. An overview of the study design is detailed in Figure 1.

203 Initially, we examined the validity of our genetic instrument as a pharmacological proxy for 204 downregulated IL-18 signaling by assessing its impact on established downstream 205 biomarkers: IL-6, C-reactive protein (CRP), interferon-gamma (IFN-γ), and tumor necrosis factor. These biomarkers were identified from pre-clinical³⁰ and early-phase clinical studies 206 of therapies targeting the IL-18 signaling pathway.^{31, 32} Circulating levels of IL-1β were 207 208 selected as a negative control because as IL-1 β functions through an alternative signaling 209 pathway, its levels are not expected to be affected by IL-18 signaling. Two-sample *cis*-MR 210 was then used to elucidate the relationship between on-target reduced IL-18 signaling and the 211 risk of cardiovascular disease. Subsequent analyses assessed the bidirectional effects between 212 liability to diseases identified in primary analyses and circulating IL-18 levels. We undertook 213 a mediation analysis to identify pathways that contribute to the effect of genetically predicted 214 IL-18 blockade on cardio-embolic stroke. Finally, we explored the effect of downregulated 215 IL-18 signaling on longevity and a selection of clinically relevant outcomes to identify 216 potential adverse outcomes associated with an impaired host immune response. We used parental age at death, a partially heritable trait, as an indirect measure of longevity.³³ 217

218

219 Data Sources

220 For our primary CVD outcomes, we obtained summary statistics for stroke from

221 GIGASTROKE ($N_{cases} = 62,100$), peripheral arterial disease from the GoLEAD and Summit

222 Consortium ($N_{cases} = 12,086$), coronary artery disease from CARDIoGRAMplusC4D (N_{cases}

223 = 181,522), HF from Aragram et al's GWAS of ischaemic and non-ischaemic HF in the UK

Biobank (UKB) ($N_{cases} = 6,504$), dilated cardiomyopathy from Ning et al.'s GWAS in UKB

 $(N_{cases} = 1,303)$ and AF from Nielsen's genome-wide association meta-analysis with UKB

excluded ($N_{cases} = 45,800$). Summary statistics for lipid traits were derived from the Global

227 Lipids Genetics Consortium (N = 1,320,016) and a UKB GWAS conducted by Richardson et

228	al (N = $115,082$). For inflammatory markers, summary statistics were sourced as follows:
229	CRP from Said et al.'s GWAS involving over 500,000 individuals; tumor necrosis factor from
230	The INTERVAL Study (N = 3,301); interferon-gamma from Ahola-Olli et al.'s GWAS (N =
231	7,701); IL-1 beta from deCODE (N = 35,559); CXCL10 from Gudjonsson et al.'s GWAS (N
232	= 5,366), and IL-6 from a genome-wide meta-analysis by Zhao et al (N = 14,743). Summary
233	statistics for cardiac magnetic resonance (CMR) imaging traits were sourced from four
234	GWAS in UKB ($N_{range} = 16,920-41,505$). Detailed information on all data sources used in
235	this study is available in the Supplementary Methods or Supplementary Table 1.

236

237 Instrumental variable selection

238 Summary statistics for circulating IL-18 concentration were obtained from the Scallop 239 Consortium's genome-wide association meta-analysis of 90 Olink-measured proteins from 13 contributing cohorts containing 21,758 European individuals.³⁴ We identified common 240 241 (minor allele frequency >0.01) *cis*-genetic variants associated with circulating IL-18 242 concentration at genome-wide significance from within a 100kb flanking region of the IL-18 gene (hg19: chromosome 11: 112013974-112034840). Variants were then clumped using a 243 linkage disequilibrium (LD) threshold $r^2 < 0.1$ and a distance threshold of 100kb, utilizing 244 245 data from the 1000 Genomes Project European reference panel. This methodology selected 246 five partially correlated *cis*-variants with the strongest association with circulating IL-18 247 concentration within each LD region from around the IL-18 gene, as described in 248 Supplementary Table 2. Instrument strength was assessed through the calculation of an F-249 statistic and a mean F-statistic >10 was considered strong. For bidirectional MR analyses, we 250 created instruments for each cardiometabolic disease by selecting genetic variants associated with each outcome at genome-wide significance from throughout the genome. We clumped 251 252 these variants using an LD threshold of $r^2 < 0.001$ and a distance threshold of 10,000 kb. We

relaxed our significance threshold for HF to 5×10^{-7} due to a scarcity of genome-wide significant variants.

255

256 Statistical analysis

257 Mendelian randomization analyses

258 Causal estimates from MR analyses rely on three key assumptions: (i) relevance, where the 259 genetic instrument must be associated with the exposure; (ii) independence, where the 260 instrument is not associated with any confounders of the exposure-outcome relationship; and 261 (iii) exclusion restriction, where the instrument affects the outcome solely through its effect on the exposure.³⁵ Random-effects inverse-variance weighted (IVW) models were used in 262 263 primary MR analyses. For all significant associations, we conducted a range of sensitivity 264 analyses to assess for possible violations of the underlying assumptions of MR, including 265 weighted median and mode to assess for consistency of results, MR Egger to assess for directional pleiotropy and MR PRESSO to adjust for the effect of potential outliers.³⁵ We 266 267 repeated all analyses using generalized inverse variance weighted MR, which adjusts for residual pairwise LD among variants included in our IL-18 instrument.³⁵ 268

269

270 Mediation analysis

Following the methodology described by Woolf et al., we employed two-step *cis*-MR to calculate the proportion of the effect of downregulated IL-18 signaling on cardio-embolic stroke that was mediated by downstream cardiometabolic traits identified in primary analyses.³⁶ This involved estimating the effect of IL-18 on each potential mediator, followed by assessing the impact of each mediator on the outcome while adjusting for IL-18. We then calculated the proportion of IL-18's overall effect on cardioembolic stroke mediated by each outcome by dividing the indirect effect by the total effect. We used the weighted median

estimator for the mediation analysis if heterogeneity was detected in the inverse-variance
weighted MR estimate. Standard errors and the 95% CI for the proportion mediated were
calculated using the delta method.³⁷

281

282 Colocalization and LD check

283 Bayesian colocalization was used to determine if levels of circulating IL-18 and our primary 284 outcomes share a single causal variant at the IL-18 gene locus, which may indicate a causal pathway between the exposure and the outcome.³⁸ Colocalization involves calculating 285 286 posterior probabilities (PP) for five hypotheses to assess the likelihood that the genetic 287 variants influencing two traits at a specific locus are overlapping or distinct. H0 suggests that 288 there is no genetic association with either trait; H1 and H2 suggest that only the first or 289 second trait has a genetic association; H3 suggests that both traits are associated but have 290 different causal variants; and H4 suggests that both traits are associated and share a single 291 causal variant. Colocalization analyses rely on a well-powered outcome GWAS and sufficient variant coverage in the region of interest.^{38, 39} A posterior probability (PP) for H3 (distinct 292 293 causal variant) and H4 (shared causal variant) less than 0.8, in the context of a statistically 294 significant MR association, may signal an underpowered outcome GWAS to determine if the 295 association is due to a shared causal variant or from a confounding variant in LD (i.e. 296 horizontal pleiotropy). LD Check is an alternative method for co-localization when variant coverage is insufficient for Bayesian colocalization.³⁹ LD Check estimates the LD between 297 298 the sentinel IL-18 variant and the top 30 variants from the same genomic region in each 299 outcome study. Causality with the sentinel IL-18 variant is suggested if at least one of the top 30 SNPs exhibits strong LD $(r^2 > 0.8)$.³⁹ 300

301

303 *Reporting and packages*

304 Results from MR analyses are reported as odds ratios (OR) for binary outcomes and standard deviation (SD) difference for continuous outcomes per SD lower in genetically predicted IL-305 306 18 levels. Results from bidirectional MR analyses are reported as the effect of a one-unit 307 increase in the log odds of genetic liability for each cardiometabolic disease. We applied the 308 Benjamini-Hochberg method to control for the false discovery rate (FDR) across all 309 phenotypes and report the unadjusted and FDR-adjusted p-values. Associations with a 310 nominal p-value <0.05 and a Benjamini-Hochberg adjusted p-value >0.05 were deemed 311 suggestive. Associations with a Benjamini-Hochberg adjusted p-value <0.05 were considered 312 significant. Analyses were performed in R (v4.2.1; R Foundation for Statistical Computing) 313 with the TwoSampleMR, MendelianRandomisation, Coloc and TwoStepCisMR packages. 314 315 **Standard Protocol Approvals, Registrations, and Patient Consents** 316 All contributing studies obtained appropriate informed consent from participants and received 317 ethical approval before commencement. This study was conducted in adherence to the

318 guidelines for Strengthening the Reporting of Observational Studies in Epidemiology –

319 Mendelian randomization (STROBE- MR), as detailed in the Supplement.

320

321 Data availability

322 This study utilizes publicly available, summary-level GWAS data that can be accessed

323 through the GWAS Catalogue (<u>https://www.ebi.ac.uk/gwas/home</u>) and the Integrative

324 Epidemiology Unit (IEU) OpenGWAS project (https://gwas.mrcieu.ac.uk/) or specific cohort

325 portals, including The Scallop Consortium (https://zenodo.org/records/2615265), The Centre

326 for Statistical Genetics (<u>https://csg.sph.umich.edu/willer/public/afib2018/</u>), Pan-UK Biobank

327 (<u>https://pan.ukbb.broadinstitute.org/</u>), The Human Genetics Amplifier (HuGeAMP)

- 328 (<u>https://kp4cd.org/node/169</u>), The Usher Institute of Population Health Sciences and
- 329 Informatics (<u>https://datashare.ed.ac.uk/handle/10283/3209</u>), The Cardiovascular Disease
- 330 Knowledge Portal (<u>https://cvd.hugeamp.org/downloads.html</u>), The NBDC Human Database
- 331 (https://humandbs.dbcls.jp/en/), The Complex Trait Genetics Lab
- 332 (https://cncr.nl/research/summary_statistics/) and FinnGen
- 333 (<u>https://www.finngen.fi/en/access_results</u>).
- 334
- 335 Results

336 Genetically downregulated IL-18 signaling and cardiometabolic biomarkers

- 337 Our instrument for lower genetically downregulated IL-18 signaling, composed of 5 variants,
- had a mean *F*-statistic of 124, indicating an appropriate average instrument strength, and
- explained 3.64% of the total variation of circulating IL-18 levels in the Scallop Consortium.
- 340 Lower genetically predicted IL-18 levels were associated with several downstream
- 341 biomarkers of IL-18 signaling, suggesting that our instruments represented a proxy for IL-18
- 342 signaling downregulation. The downstream biomarkers that were significantly associated
- 343 with genetically proxied IL-18 levels included C-reactive protein (CRP) (SD change -0.02,
- 344 95% CI -0.03, -0.02, p_{fdr} <0.001), tumor necrosis factor (SD change -0.19, 95% CI -0.25, -
- 345 0.14, p_{fdr} <0.001), interferon-gamma (IFN-y) (SD change -0.15, 95% CI -0.22, -0.08, p_{fdr}
- 346 <0.001) and CXCL10 (SD change -0.13, 95% CI -0.16, -0.09, p_{fdr} <0.001), but not IL-1 β or
- 347 IL-6 (Figure 2). Lower genetically predicted IL-18 levels were associated with higher
- diastolic blood pressure (SD change 0.02, 95% CI 0.02, 0.03, $p_{fdr} = <0.001$) and body mass
- index (SD change 0.02, 95% CI 0.02, 0.01, p_{fdr} =0.017), but had no association with lipid
- 350 subfractions.
- 351
- 352

353

354 Genetically downregulated IL-18 signaling and cardiometabolic diseases Lower genetically predicted IL-18 levels (1 SD decrease in IL-18 levels) were associated 355 356 with 15% lower odds of cardio-embolic stroke (OR 0.85, 95% CI 0.79-0.92, $p_{fdr} < 0.001$, 357 Figure 3) and 9% lower odds of peripheral arterial disease (OR 0.91, 95% CI 0.84-0.97, p_{fdr} 358 =0.027), but had no association with other stroke subtypes, coronary artery disease or a ortic 359 stenosis. In UKB, lower genetically predicted IL-18 levels were also associated with reduced 360 odds of both all-cause HF (OR 0.83, 95% CI 0.75-0.91, p_{fdr} <0.001) and dilated 361 cardiomyopathy (OR 0.74, 95% CI 0.58-0.93, pfdr =0.031). When assessing related cardio-362 metabolic diseases, lower genetically predicted IL-18 levels were associated with lower odds 363 of chronic kidney disease (CKD) (OR 0.91, 95% CI 0.84-0.99, p_{fdr}=0.027), and type 2 364 diabetes mellitus (T2DM) (OR 0.97, 95% CI 0.95-0.99, $p_{fdr} = 0.027$). Additionally, there was 365 a trend towards an association between lower genetically predicted IL-18 levels and reduced 366 risk of AF (OR 0.94, 95% CI 0.89-0.99, $p_{fdr} = 0.054$), which did not maintain significance 367 following false discovery rate adjustment. Associations for HF were successfully replicated 368 in a non-overlapping sample of American cohort studies (OR 0.85, 95% CI 0.75-0.95, p 369 =0.004, Supplementary Table 3). For AF, results were directionally similar but did not reach 370 statistical significance in the UK Biobank (UKB) (OR 0.96, 95% CI 0.92-1.00, p = 0.061). 371 372 In colocalization analyses between IL-18 and AF, peripheral arterial disease, HF, cardio-

embolic stroke, CKD and T2DM, the posterior probabilities of *H3* and *H4* were less than 0.8
and this along with the low minimum p-values in the *IL-18* gene region in each of the
outcome summary statistics implies suboptimal power for colocalization, the presence of
confounding by LD or multiple causal variants within the gene region. We subsequently
conducted an LD Check analysis and obtained the LD correlation between the sentinel

378	variant (rs5744249) from the IL-18 gene locus and the top 30 variants within 100kb of
379	rs5744249 with the lowest p-values from the cardio-embolic stroke, AF, peripheral arterial
380	disease, HF, CKD and T2DM summary statistics. At least one top cis-variant from each
381	outcome dataset, except for peripheral arterial disease, exhibited strong LD ($r^2 > 0.8$) with the
382	sentinel variant. This suggests potential causal associations between IL-18 and cardio-
383	embolic stroke, AF, HF, CKD and T2DM
384	
385	Genetically downregulated IL-18 signaling and cardiac magnetic resonance imaging
386	traits
387	In UKB, there were directionally consistent improvements in all measures of cardiac
388	structure and function with lower genetically predicted IL-18 levels as displayed in Figure 3,
389	with the exception of left and right ventricular ejection fractions. Following adjustment for
390	multiple testing, lower genetically predicted IL-18 levels were associated with a reduction in
391	left atrial size (SD change -0.02, 95% CI -0.03, -0.00, $p_{fdr} = 0.022$) and left ventricular end-
392	systolic volume (SD change -0.08, 95% CI -0.13, -0.02, p _{fdr} = 0.039).
393	
394	Genetically downregulated IL-18 signaling and potential adverse effects
395	Lower genetically predicted IL-18 levels were associated with a longer parental lifespan, an
396	indirect measure of longevity (SD change 0.02 years, 95% CI 0.01-0.04, $p_{fdr} = 0.005$), and
397	reduced risk of a range of autoimmune diseases, including atopic dermatitis (OR 0.86, 95%
398	CI 0.83-0.90, p _{fdr} <0.001), psoriasis (OR 0.84-0.89, p _{fdr} <0.001), asthma (OR 0.90, 95% CI
399	0.86-0.94, p_{fdr} <0.001), and rheumatoid arthritis (OR 0.85, 95% CI 0.81-0.90, p_{fdr} < 0.001,
400	Figure 4). There was also a trend toward an association between lower genetically predicted
401	IL-18 levels and reduced risk of ulcerative colitis (OR 0.88, 95% CI 0.79-0.98, $p_{fdr} = 0.051$),
402	which did not maintain significance following false discovery rate adjustment. While lower

403	genetically predicted IL-18 levels were not significantly associated with an increased risk of
404	infection, it was associated with higher odds of lung cancer (OR 1.15, 95% CI 1.11-1.20, p_{fdr}
405	<0.001) and multiple sclerosis (OR 1.17, 95% CI 1.03-1.32, p _{fdr} = 0.041).
406	
407	Bidirectional relationship between cardiometabolic diseases and IL-18 levels
408	In reverse MR analyses, genetic liability to cardio-embolic stroke was not significantly
409	associated with circulating levels of IL-18 (β representing the effect of one unit increase in
410	the log odds of genetic liability for cardioembolic stroke -0.03, 95% CI -0.08-0.02, $p =$
411	0.267). Similarly, circulating levels of IL-18 were not affected by genetic liability to AF (β
412	0.00, 95% CI -0.03-0.04, p 0.879), HF (β -0.03, 95% CI -0.22-0.16, p =0.743), CKD (β 0.01,
413	95% CI -0.07-0.06, p = 0.821), peripheral arterial disease (β 0.07, 96% CI -0.26-0.39, p =
414	0.686), or higher BMI (β 0.05, 95% CI -0.01-0.12, p = 0.104).
415	
416	Mediation analyses
417	We performed two-step network MR mediation analyses to quantify the extent to which
418	downstream cardiometabolic traits mediate the relationship between IL-18 signaling and
419	cardio-embolic stroke. We observed that genetic liability to AF accounted for 25% of the
420	total effect of lower genetically predicted IL-18 levels on cardio-embolic stroke (proportion-
421	mediated 25.1%, 95% CI 22.4-27.8%, p <0.001, Supplementary Table 4).
422	
423	Genetic liability to all-cause HF accounted for 5.6% of the total effect (proportion-mediated
424	5.3%, 95% CI 1.7-8.8%, p =0.003), while genetic liability to CKD mediated 2.8% of the total
425	effect of downregulated IL-18 signaling on cardio-embolic stroke (proportion-mediated

426 2.8%, 95% CI 0.1-5.7%, p =0.054). However, BMI had a more modest impact, mediating

427 1.61% of the total effect (proportion-mediated 1.6%, 95% CI -2.0-5.2%, p =0.383), while

428	genetic liability to T2DM had little impact, mediating only 0.8% of the total effect of lower
429	genetically predicted IL-18 levels on cardio-embolic stroke (proportion-mediated 0.8%, 95%
430	CI -2.8-4.4%, p =0.657

431

432 Sensitivity analyses

The MR estimates from generalized IVW, weighted median, weighted mode, MR Egger, and MR PRESSO are reported in Supplementary Tables 5.1-5.24. No heterogeneity was observed across all MR analyses, as indicated by Cochrane's Q and Rucker's Q statistics. Estimates were consistent with primary results when using generalized IVW MR to model residual LD, and directionally similar across weighted median and weighted mode methods. The p-values for the MR Egger intercept test and the global MR PRESSO test were not significant,

439 suggesting an absence of marked pleiotropy.

440

441 **Discussion**

442 Leveraging data from large-scale genomic, proteomic and imaging studies, we have 443 demonstrated new and important evidence linking IL-18 signaling to HF, peripheral arterial 444 disease, atrial cardiomyopathy, and cardio-embolic stroke. Lower genetically predicted IL-18 445 levels were associated with reduced concentrations of several downstream inflammatory 446 cytokines and exhibited protective effects on cardiac structure and function. Genetic liability 447 to AF and HF mediated a significant proportion of the risk-lowering effect of IL-18 signaling 448 on cardioembolic stroke. Lower genetically predicted IL-18 levels were associated with a 449 favorable metabolic profile overall, with a lower risk of T2DM, CKD, autoimmune disease, 450 and enhanced longevity.

452 The present data are supported by several lines of evidence from experimental models, 453 observational studies, and emerging data from RCTs implicating the NLRP3-inflammasome 454 and IL-18 activation in HF and AF. The NLRP3-inflammasome is activated by pro-455 inflammatory mediators, such as IL-1ß and TNF-alpha, damage-associated molecular 456 patterns (DAMPs) secondary to ischemia-reperfusion injury, and angiotensin II overexpression from renin-angiotensin activation.^{4, 21, 40} IL-18 activation ensues secondary to 457 NLRP3 inflammasome formation in leukocytes, endothelial cells, fibroblasts, and 458 cardiomyocytes.²¹ The binding of IL-18 to its receptor triggers the recruitment of tumor 459 460 necrosis factor receptor-associated factor-6 (TRAF6), and the activation of nuclear factor Kappa B (NF- κ B) and p38 mitogen-activated protein kinase (MAPK).²¹ This cascade results 461 in the synthesis of secondary inflammatory mediators, including IFN- γ and TNF- α .³⁰ In-vitro 462 and animal models have demonstrated that disrupting the IL-18 signaling pathway can reduce 463 myocardial hypertrophy, improve contractile function, and decrease fibrosis.^{21, 22} IL-18 464 465 mediates β-adrenergic receptor stimulation-induced macrophage infiltration, cardiac inflammation, and fibrosis.²⁰ IL-18 also triggers apoptosis in microvascular endothelial cells 466 through activation of NF-kB and upregulates the expression of osteopontin, fibronectin, and 467 matrix metalloproteinase 2 (MMP-2) in human cardiac fibroblasts.²¹ In humans, IL-18 levels 468 increase in proportion to disease progression in both HF²³ and AF.^{41, 42} In the Atherosclerosis 469 470 Risk in Communities (ARIC) study circulating IL-18 in mid-life was associated with future risk of HF.²⁴ Similarly, Henry et al.'s meta-analysis of four population-based studies 471 demonstrated an association between IL-18 levels and risk of incident HF.²⁷ 472 473 474 Our results suggest that the IL-18 signaling pathway is a viable treatment target in AF, HF 475 and cardio-embolic stroke. Our data were derived from non-overlapping cohorts and

demonstrated biologically consistent results, implicating IL-18 at the center of multiple

477	downstream pro-inflammatory pathways, cardiac remodeling, AF, HF, and ultimately cardio-
478	embolic stroke. Our two-step cis-MR analysis suggests that the reduced risk of cardioembolic
479	stroke associated with downregulated IL-18 signaling is likely mediated through its
480	protective effects against lifetime cardiac remodeling, cardiomyopathy, and AF. Our results
481	are supported by Schmidt et al.'s recent cis-MR study which showed that targeting the IL-18
482	receptor is associated with four left ventricular CMR traits and risk of dilated
483	cardiomyopathy. ⁴³ Furthermore, in their candidate gene study, Wang et al. demonstrated that
484	three variants associated with IL18 gene expression increased risk of AF and left atrial
485	enlargement. ⁴⁴

486

The global burden of stroke, HF and AF is increasing.^{45, 46} There is a pressing need to identify 487 488 and develop disease-modifying therapies that prevent stroke and slow disease progression in 489 both HF and atrial cardiopathy. In atherosclerosis, colchicine and canakuinumab have both 490 shown benefit in reducing major adverse cardiovascular events (MACE) in coronary artery 491 disease.^{1, 2} Although colchicine did not reduce the risk of MACE after non-cardioembolic 492 stroke, a 20% reduced risk was observed in an on-treatment analysis suggesting a possible biological effect.³ Apart from the treatment of atherosclerosis, there is also increasing interest 493 494 in targeting inflammation in HF and AF. Whilst there is some evidence that colchicine reduces the risk of postoperative AF following cardiac surgery and decreases AF recurrence 495 after pulmonary vein isolation or ablation⁴⁷, a recent RCT was neutral.¹² Currently, no 496 497 licensed anti-inflammatory therapies have been proven to prevent hard outcomes in HF. RCTs investigating the potential of TNF α inhibition were neutral.^{10, 11} Anakinra, an anti-IL-1 498 499 monoclonal antibody, improved several surrogate markers of cardiac function but failed to significantly reduce hospitalization for HF or death.⁴⁸ While genetic studies have identified 500 the IL-6 signaling pathway as a potential druggable target for AF, they do not support a 501

causal role in HF or cardio-embolic stroke.¹⁶ Consequently, future experimental work and
RCTs should now focus on the potential benefit of IL-18 pathway suppression in the
treatment of HF and the prevention of cardio-embolic stroke.

505

506 Our results suggest that IL-18 inhibition would likely have a favourable cardio-metabolic 507 profile. Downregulated IL-18 signaling reduced risk of CKD and T2DM, which are key risk 508 factors for cardiovascular disease. However, we did observe that IL-18 suppression was 509 associated with marginal increases in diastolic blood pressure and BMI while having minimal 510 effect on lipid fractions and systolic blood pressure. The clinical relevance of these findings 511 will need to be explored in future studies. We show that downregulated IL-18 signaling is 512 associated with lower risk of atopic disease, which supports the rationale for ongoing clinical 513 trials of IL-18 signaling-blocking therapies in atopic dermatitis. Promising agents for 514 potential repurposing in cardiovascular disease include GSK1070806 and Camoteskimab, 515 which are human monoclonal antibodies targeting IL-18, as well as tadekinig α , a 516 recombinant human IL-18 binding protein that sequesters IL-18. Immunomodulatory 517 therapies carry potential risks, notably with respect to host response to infections and 518 malignancy. Our study shows that downregulated IL-18 signaling increases the risk of lung 519 cancer, but not other cancers or infection. Most importantly, we show that reduced IL-18 520 signaling is associated with enhanced lifespan, indicative of a net positive effect on all-cause 521 mortality.

522

523 Previous data from experimental models and some epidemiological studies suggested that IL524 18 was associated with atherosclerosis and coronary disease.^{26, 49} Apart from a modest
525 association with peripheral arterial disease that did not have LD Check support, we did not
526 find any compelling evidence that IL-18 signaling is causally associated with atherosclerotic

527 endpoints. On the contrary, prior MR studies have implicated IL-6 signaling in coronary 528 artery disease and atherosclerotic stroke.¹⁶ Together with data from CANTOS suggesting the 529 potential benefit of IL-1β-IL-6 axis suppression,² our analysis supports the rationale of 530 ongoing trials focusing on the high potential of IL-6 pathway inhibition in atherosclerosis.¹⁷ 531

532 Our study has several strengths. The MR study design minimizes bias from reverse causation 533 and environmental confounders, while cis-MR provides an evaluation of the effects of directly perturbing a drug target on disease outcomes. We leveraged large multi-omic 534 535 datasets to uncover new insights into how downregulated IL-18 signaling influences 536 cardiovascular disease. Moreover, we developed a robust genetic cis-instrument that mirrors 537 the effects of reduced IL-18 signaling on downstream biomarkers and conducted a 538 comprehensive set of mediation and sensitivity analyses to improve confidence in our 539 findings. We were also able to validate our findings for HF in independent cohorts. We 540 acknowledge some limitations. Although we utilized large genomic consortia for outcome 541 summary statistics, our analyses may have been underpowered to detect associations with 542 rarer phenotypes. Effect sizes derived from drug-target MR studies reflect lifelong 543 perturbation of the drug target rather than the short-term treatment durations typically seen in 544 clinical practice, potentially leading to significant differences in the observed benefits. Two-545 sample MR methods assume a linear relationship between genetically proxied exposures and 546 outcomes. In cases of non-linearity, the MR estimates reflect a population average effect 547 rather than capturing potentially varying effects across different levels of exposure. Similarly, 548 in clinical practice, the biological response to drugs often requires surpassing a specific 549 therapeutic dose, a detail that two-sample MR studies might not capture due to their reliance 550 on average effects. Two-step cis-MR relies on several assumptions including linearity, and 551 may yield unreliable estimates when the mediator or outcome is not continuous, potentially

552 impacting the accuracy of our effect size estimates and the interpretation of IL-18 signaling 553 mediation on cardio-embolic stroke through AF, HF, CKD, and T2DM. Our analyses were 554 limited to individuals of European ancestry to minimize confounding by population 555 stratification and the potential impact of downregulated IL-18 signaling on risk of cardio-556 vascular disease in non-European ancestries remains to be explored. Finally, our MR 557 estimates reflect the impact of downregulated IL-18 signaling on incident disease, and it 558 remains unclear how appliable these findings are to individuals with established disease, who 559 are more likely to be prioritized for treatment and inclusion in clinical trials. 560 561 In conclusion, this study used large-scale multi-omic data to explore the effects of genetically 562 downregulated IL-18 signaling on cardiovascular disease. We provide compelling data which 563 suggests the IL-18 pathway is causally implicated in the evolution of cardiomyopathy, from 564 structural remodelling through to an increased risk of HF and cardio-embolic stroke. These 565 data strongly suggest that IL-18 represents a viable target for the prevention and treatment of 566 stroke and heart failure, with a favorable cardiometabolic and autoimmune profile, that 567 warrants further exploration in clinical trials. 568

569 Sources of funding

570 PJK has received funding from the Irish Health Research Board. DG is supported by the

571 British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College
572 London.

573

574 **Disclosures**

575 The authors have no relevant conflicts of interest to disclose.

References

578	1.	Xia M, Yang X, Qian C. Meta-analysis evaluating the utility of colchicine in				
579		secondary prevention of coronary artery disease. Am J Cardiol. 2021;140:33-38				
580	2.	Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.				
581		Antiinflammatory therapy with canakinumab for atherosclerotic disease. New				
582		England Journal of Medicine. 2017;377:1119-1131				
583	3.	Kelly P, Lemmens R, Weimar C, Walsh C, Purroy F, Barber M, et al. Long-term				
584		colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke				
585		(convince): A randomised controlled trial. The Lancet. 2024				
586	4.	Yao C, Veleva T, Scott L, Cao S, Li L, Chen G, et al. Enhanced cardiomyocyte nlrp3				
587		inflammasome signaling promotes atrial fibrillation. Circulation (New York, N.Y.).				
588		2018;138:2227-2242				
589	5.	McKechnie DGJ, Papacosta AO, Lennon LT, Welsh P, Whincup PH, Wannamethee				
590		SG. Inflammatory markers and incident heart failure in older men: The role of nt-				
591		probnp. Biomarkers in Medicine. 2021;15:413-425				
592	6.	Szabo TM, Frigy A, Nagy EE. Targeting mediators of inflammation in heart failure: A				
593		short synthesis of experimental and clinical results. Int J Mol Sci. 2021;22				
594	7.	Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, et al. A				
595		multimarker approach to assess the influence of inflammation on the incidence of				
596		atrial fibrillation in women. Eur Heart J. 2010;31:1730-1736				
597	8.	Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal				
598		RA, et al. Inflammation as a risk factor for atrial fibrillation. <i>Circulation</i> .				
599		2003;108:3006-3010				
600	9.	Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, et al.				
601		Interleukin-6 and c-reactive protein and risk for death and cardiovascular events in				
602		patients with atrial fibrillation. Am Heart J. 2015;170:1151-1160				
603	10.	Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al.				
604		Targeted anticytokine therapy in patients with chronic heart failure: Results of the				
605		randomized etanercept worldwide evaluation (renewal). Circulation. 2004;109:1594-				
606		1602				
607	11.	Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-				
608		blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to				
609		tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results				
610		of the anti-tnf therapy against congestive heart failure (attach) trial. Circulation.				
611		2003;107:3133-3140				
612	12.	Benz AP, Amit G, Connolly SJ, Singh J, Acosta-Vélez JG, Conen D, et al. Colchicine				
613		to prevent atrial fibrillation recurrence after catheter ablation: A randomized, placebo-				
614		controlled trial. Circulation: Arrhythmia and Electrophysiology. 2024;17:e01238				
615	13.	Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1				
616		and the inflammasome as therapeutic targets in cardiovascular disease. Circulation				
617		research. 2020;126:1260-1280				
618	14.	Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al.				
619		Inflammatory cytokines and risk of coronary heart disease: New prospective study				
620		and updated meta-analysis. Eur Heart J. 2014;35:578-589				
621	15.	Papadopoulos A, Palaiopanos K, Bjorkbacka H, Peters A, de Lemos JA, Seshadri S, et				
622		al. Circulating interleukin-6 levels and incident ischemic stroke: A systematic review				
623		and meta-analysis of prospective studies. <i>Neurology</i> . 2021				

624 16. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M, et al. Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: 625 626 A mendelian randomization study. Circ Genom Precis Med. 2020;13:e002872 627 17. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in 628 cardiovascular disease. Circ Res. 2021;128:1728-1746 629 McCabe JJ, Walsh C, Gorey S, Harris K, Hervella P, Iglesias-Rey R, et al. C-reactive 18. 630 protein, interleukin-6, and vascular recurrence after stroke: An individual participant 631 data meta-analysis. Stroke. 2023 632 19. Toldo S, Mezzaroma E, O'Brien L, Marchetti C, Seropian IM, Voelkel NF, et al. 633 Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol 634 Heart Circ Physiol. 2014;306:H1025-1031 Xiao H, Li H, Wang J-J, Zhang J-S, Shen J, An X-B, et al. Il-18 cleavage triggers 635 20. 636 cardiac inflammation and fibrosis upon β -adrenergic insult. European Heart Journal. 2017:39:60-69 637 638 21. O'Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, et al. 639 Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. 640 Mol Med. 2014;20:221-229 641 Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, Larson DF. Il-18 induction 22. 642 of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J 643 Physiol Heart Circ Physiol. 2009;297:H76-85 644 23. Yamaoka-Tojo M, Tojo T, Inomata T, Machida Y, Osada K, Izumi T. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/th2 cytokine imbalance 645 646 exaggerates the pathophysiology of advanced heart failure. J Card Fail. 2002;8:21-27 647 24. Jia X, Buckley L, Sun C, Al Rifai M, Yu B, Nambi V, et al. Association of interleukin-648 6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis risk 649 in communities study. European Journal of Preventive Cardiology. 2023;30:1731-650 1740 Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. 651 25. 652 Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis. European Heart Journal. 2013:35:578-589 653 654 26. Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE, Woodward M, et al. Interleukin 18 and coronary heart disease: Prospective study and systematic 655 656 review. Atherosclerosis. 2011;217:227-233 Henry A, Gordillo-Marañón M, Finan C, Schmidt AF, Ferreira JP, Karra R, et al. 657 27. Therapeutic targets for heart failure identified using proteomics and mendelian 658 659 randomization. Circulation. 2022;145:1205-1217 660 28. Gill D, Georgakis M, Walker V, Schmidt A, Gkatzionis A, Freitag D, et al. Mendelian randomization for studying the effects of perturbing drug targets [version 2; peer 661 662 review: 3 approved, 1 approved with reservations]. Wellcome Open Research. 2021;6 663 29. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024;629:624-629 664 665 30. Kaplanski G. Interleukin-18: Biological properties and role in disease pathogenesis. Immunological reviews. 2018;281:138-153 666 Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-label, 667 31. 668 multicentre, dose-escalating phase ii clinical trial on the safety and efficacy of 669 tadekinig alfa (il-18bp) in adult-onset still's disease. Annals of the Rheumatic 670 Diseases. 2018;77:840-847 671 32. Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, et al. A dose-escalation study of recombinant human interleukin-18 using two different 672

673		schedules of administration in patients with cancer. Clinical Cancer Research.
674		2008;14:3462-3469
675	33.	Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Human
676		longevity is influenced by many genetic variants: Evidence from 75,000 uk biobank
677		participants. Aging (Albany NY). 2016;8:547
678	34.	Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, et al.
679		Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931
680		individuals. Nature metabolism. 2020;2:1135-1148
681	35.	Richmond RC, Smith GD. Mendelian randomization: Concepts and scope. Cold
682		Spring Harbor perspectives in medicine, 2022:12:a040501
683	36.	Woolf B. Zagkos L. Gill D. Twostepcism: A novel method and r package for
684	000	attenuating bias in cis-mendelian randomization analyses. <i>Genes</i> , 2022:13:1541
685	37	Tofighi D MacKinnon DP Rmediation: An r package for mediation analysis
686	57.	confidence intervals <i>Rehavior research methods</i> 2011:43:692-700
687	38	Zuber V Grinberg NF Gill D Manipur I Slob FA Patel A et al Combining
688	50.	evidence from mendelian randomization and colocalization: Review and comparison
680		of approaches The American Journal of Human Ganatics 2022:100.767-782
600	30	Zheng I. Haberland V. Baird D. Walker V. Havcock PC. Hurle MR. et al. Phenome-
601	57.	wide mendelian randomization manning the influence of the plasma proteome on
602		complex discusses. Nature genetics, 2020:52:1122, 1121
602	40	Mazzaroma E. Abbata A. Talda S. The inflammasoma in heart failure. Curr Onin
604	40.	Dhusiol 2021.10.105 112
094 605	41	Physiol. 2021;19:105-112 Liv V Lue D Liv E Liv T Vu C Lione V et al Mirre 21 and il 18 lovels in left
695	41.	Liu I, Luo D, Liu E, Liu I, Au G, Liang A, et al. Mirina21 and II-16 levels in left
090 607		atrial blood in patients with atrial fibrillation undergoing cryoablation and their
6097		Electron busieles 2022.64.111 120
098	40	<i>Electrophysiology</i> . 2022;04:111-120
099 700	42.	Luan Y, Guo Y, Li S, Yu B, Zhu S, Li S, et al. Interleukin-18 among atrial fibrillation
700	40	patients in the absence of structural heart disease. Europace. 2010;12:1/13-1/18
701	43.	Schmidt AF, Bourliss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, et al.
702		Druggable proteins influencing cardiac structure and function: Implications for heart
703	4.4	failure therapies and cancer cardiotoxicity. <i>Science advances</i> . 2023;9:eadd4984
704	44.	Wang Y-H, Fu L, Wang B, Li S-F, Sun Z, Luan Y. Genetic variants of interleukin-18
705		are associated with reduced risk of atrial fibrillation in a population from northeast
706		china. Gene. 2017;626:269-274
707	45.	Savarese G, Becher PM, Lund LH, Seterovic P, Rosano GM, Coats AJ. Global burden
708		of heart failure: A comprehensive and updated review of epidemiology.
709		Cardiovascular research. 2022;118:3272-3287
710	46.	Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016: A
711		systematic analysis for the global burden of disease study 2016. <i>Lancet Neurol</i> .
712		2019;18:439-458
713	47.	Kommu S, Arepally S. The effect of colchicine on atrial fibrillation: A systematic
714		review and meta-analysis. Cureus. 2023;15
715	48.	Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, et al.
716		Interleukin-1 blockade in recently decompensated systolic heart failure: Results from
717		redhart (recently decompensated heart failure anakinra response trial). Circulation:
718		Heart Failure. 2017;10:e004373
719	49.	Wang J, Sun C, Gerdes N, Liu C, Liao M, Liu J, et al. Interleukin 18 function in
720		atherosclerosis is mediated by the interleukin 18 receptor and the na-cl co-transporter.
721		<i>Nature Medicine</i> . 2015;21:820-826
722		

723 Figure 1. Overview of the study design.

- 524 Stage 1 includes a graphical depiction of the interleukin-18 signaling pathway and a Manhattan plot
- illustrating the genome-wide association study of circulating concentration of interleukin-18 in the Scallop
- 726 consortium. The red line indicates the genome-wide significance threshold (5×10^{-8}) .
- 727

728 Figure 2. The association between genetically downregulated IL-18 signaling and

- 729 cardiometabolic biomarkers
- 730 Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization
- analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation; FDR, false discovery
- rate; CXCL10, C-X-C motif chemokine ligand 10.
- 733

734 Figure 3. The association between genetically downregulated IL-18 signaling and

735 cardiometabolic diseases.

- 736 Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization
- analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation.
- 738

739 Figure 4. The association between genetically downregulated IL-18 signaling and

740 cardiac magnetic resonance imaging traits.

- 741 Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization
- analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation.
- 743

744 Figure 5. The association between genetically downregulated IL-18 signaling and

745 oncological, autoimmune, neurological, and infectious diseases

- 746 Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization
- analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation.



CMR traits

Adverse effects



Outcome		Beta (95% CI)	P-val	FDR P-val
C-reactive protein		-0.02 (-0.03, -0.02)	<0.001	<0.001
Tumur necrosis factor		-0.19 (-0.25, -0.14)	<0.001	<0.001
Interferon gamma		-0.15 (-0.22, -0.08)	<0.001	<0.001
Interleukin 6	-	-0.05 (-0.11, 0.02)	0.148	0.269
Interleukin-1 beta	_ _	0.00 (-0.02, 0.02)	0.888	0.934
CXCL10	_	-0.13 (-0.16, -0.09)	<0.001	<0.001
Total LDL–C	-	0.01 (0.00, 0.01)	0.033	0.080
Total HDL-C		-0.00 (-0.01, 0.00)	0.519	0.692
Triglycerides	-	0.00 (0.00, 0.01)	0.048	0.103
Apolipoprotein B		-0.00 (-0.03, 0.03)	0.963	0.963
Apolipoprotein A1		-0.02 (-0.04, -0.00)	0.047	0.103
Systolic blood pressure		0.01 (-0.01, 0.02)	0.452	0.630
Diastolic blood pressure		0.02 (0.02, 0.03)	<0.001	<0.001
Body mass index		0.02 (0.01, 0.04)	0.004	0.017
HbA1c	-	-0.00 (-0.01, 0.00)	0.421	0.616
-0.	25 -0.2 -0.15 -0.1 -0.05 0 0.05 Change per SD lower in IL-18 levels (95% CI)		29	Э

Outcome		OR (95% CI)	P-val	FDR P-val
Coronary artery disease	-#-	1.00 (0.97, 1.02)	0.737	0.850
Peripheral artery disease		0.91 (0.84, 0.97)	0.008	0.027
Aortic stenosis -		1.01 (0.91, 1.11)	0.896	0.934
All-cause heart failure		0.83 (0.76, 0.91)	<0.001	<0.001
Non-ischaemic heart failure		0.75 (0.59, 0.95)	0.019	0.051
Dilated cardiomyopathy		0.74 (0.58, 0.93)	0.010	0.031
Large artery stroke —		1.03 (0.89, 1.20)	0.649	0.795
Cardioembolic stroke —		0.85 (0.79, 0.92)	<0.001	<0.001
Small vessel stroke		1.08 (0.93, 1.25)	0.299	0.448
All ischaemic stroke		1.02 (0.99, 1.05)	0.222	0.350
Atrial fibrillation —	∎	0.93 (0.88, 0.99)	0.022	0.054
Left bundle branch block		1.00 (0.91, 1.09)	0.954	0.963
Right bundle branch block	-	0.96 (0.80, 1.16)	0.702	0.826
Atrioventricular block -	#	1.01 (0.91, 1.12)	0.868	0.934
Abdominal aortic aneurysm	- #	1.00 (0.95, 1.05)	0.903	0.934
Chronic kidney disease	— :	0.91 (0.84, 0.97)	0.008	0.027
Type 2 diabetes mellitus	-	0.97 (0.95, 0.99)	0.008	0.027
0.60 0.70 0.80 0.90 Odds Ratio per SD lower in II	1.0 1.1 1.2 1.3 			30

Outcome		Beta (95% CI)	P-val	FDR P-val
Left atrial volume	-	-0.02 (-0.03, -0.00)	0.005	0.022
Left ventricular end systolic volume		-0.08 (-0.13, -0.02)	0.013	0.039
Left ventricular end distolic volume		-0.04 (-0.08, 0.00)	0.052	0.108
Left ventricular ejection fraction		0.03 (-0.02, 0.08)	0.299	0.448
Right ventricular end systolic volume	-	-0.02 (-0.04, 0.00)	0.062	0.124
Right ventricular end diastolic volume		-0.02 (-0.05, 0.01)	0.153	0.269
Right ventricular ejection fraction		0.02 (-0.03, 0.06)	0.446	0.630
T1 myocardial fibrosis	-8-	-0.01 (-0.04, 0.01)	0.182	0.304
	–0.2 –0.15 –0.1 –0.05 0 0.05 0.1 Change per SD lower in IL–18 levels (95% CI)		31	

Outcome	OR (95	% CI) P–val	FDR P-val
Oncological			
Lung cancer		1, 1.20) <0.001	<0.001
Breast cancer	0.94 (0.8	7, 1.02) 0.131	0.249
Prostate cancer	1.02 (0.9	5, 1.09) 0.555	0.724
Colorectal cancer	1.05 (0.8	8, 1.27) 0.577	0.737
Autoimmune			
Atopic dermatitis —	0.86 (0.8	3, 0.90) <0.001	<0.001
Psoriasis	0.84 (0.8	0, 0.89) <0.001	<0.001
Asthma —	0.90 (0.8	6, 0.94) <0.001	<0.001
Rheumatoid arthritis	0.85 (0.8	1, 0.90) <0.001	<0.001
Ulcerative colitis	0.88 (0.7	9, 0.98) 0.020	0.051
Crohn's disease	0.99 (0.8	5, 1.15) 0.863	0.934
Neurological			
Multiple sclerosis	1.17 (1.0	3, 1.32) 0.014	0.041
Alzheimer's disease	1.03 (0.9	2, 1.16) 0.611	0.764
Migraine	0.98 (0.8	4, 1.16) 0.842	0.934
Parkinson's disease	1.09 (0.9	6, 1.23) 0.175	0.301
Infectious			
Sepsis	- 0.94 (0.8	6, 1.03) 0.221	0.351
Pneumonia -	1.07 (0.9	9, 1.15) 0.078	0.151
Cellulitis		1, 1.05) 0.485	0.661
Urinary tract infection	1.07 (1.0	0, 1.14) 0.047	0.103
Tuberculosis	0.97 (0.8	1, 1.14) 0.688	0.825
0.80 0.90 1.0 Odds Ratio per SD lowe	I I.1 1.2 1.3 r in IL-18 levels (95% Cl)		32